CGTX: Cognition Therapeutics Inc

CGTX新闻

• 10:02 Cognition Therapeutics 就路易体痴呆 III 期研究的关键要素与美国 FDA 达成一致，包括患者选择、剂量、疗程和终点
• 10:02 Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints
• 10:08 Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine
• 11:32 Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of Zervimesine
• 11:32 认知治疗公司与 FDA 的 C 类会议将于 10 月 20 日举行，讨论 Zervimesine 计划中的试验
• 23:10 Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates
• 14:07 Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain